← Calendar
Readoutin 104d
AbbVie — Upadacitinib
Phase 3 primary completion: Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus.
- Date
- Mar 2027
- Type
- Readout
- Indication
- Systemic Lupus Erythematosus
Source ↗Add to calendar
Get told when this date moves
The weekly brief is free. Pro adds reminders 7 days and 1 day before.
More from AbbVie
Apr2027
Readoutin 135d
AbbVie — Mirvetuximab soravtansine plus BevacizumabPhase 3 primary completion: Mirvetuximab Soravtansine With Bevacizumab Versus Bevacizumab as Maintenance in Platinum-sensitive Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer.
Mar2027
Readoutin 104d
AbbVie — Risankizumab SCPhase 3 primary completion: A Study to Assess Adverse Events and Change in Disease Activity of Risankizumab Subcutaneous Induction Treatment for Moderately to Severely Active Crohn's Disease..
Dec2026
Readoutin 14d
AbbVie — ABBV-RGX-314Phase 3 primary completion: Pivotal 1 Study of ABBV-RGX-314 (Also Known as RGX-314) Gene Therapy Administered Via Subretinal Delivery One Time in Participants With nAMD.
Dec2026
Readoutin 14d
AbbVie — LutikizumabPhase 3 primary completion: A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa.